Comparative Analysis of HtrA3 and NGAL as Viable Biomarkers for Pre-eclampsia

IF 0.1 Q4 OBSTETRICS & GYNECOLOGY Journal of Clinical Obstetrics and Gynecology Pub Date : 2023-07-06 DOI:10.29328/journal.cjog.1001135
Chembukavu Suraj Narayanan, Samreen Sana Syed, Yadav Pankaj
{"title":"Comparative Analysis of HtrA3 and NGAL as Viable Biomarkers for Pre-eclampsia","authors":"Chembukavu Suraj Narayanan, Samreen Sana Syed, Yadav Pankaj","doi":"10.29328/journal.cjog.1001135","DOIUrl":null,"url":null,"abstract":"Pre-eclampsia is a pregnancy-associated condition, which is characterized by the onset of hypertension and proteinuria. It is one of the leading causes of maternal and neonatal mortality and this affliction has been recorded in around 8% of all pregnancies in the world. In addition to this, the etiopathology of this condition is very less understood and the resources available to diagnose and treat it are limited. Prior studies suggest more than a hundred possible diagnostic biomarkers that could be used to detect this disease early on. However, most of them are not feasible due to several reasons including stability, cost, safety, etc. Here two biomarkers HtrA3 (high-temperature requirement A3) and NGAL (Neutrophil Gelatinase Associated Lipocalin) are selected for the detection of pre-eclampsia, and we compare their efficacy in the detection of pre-eclampsia based on their specificity, ease of use, speed, stage of detection and source (invasiveness). We found that these two biomarkers are efficient under some parameters, and inefficient under others. The scoring system used in the current study suggests that NGAL is a superior biomarker. The results of this study help to develop a stronger understanding of both these biomarkers in the short and long term to classify the biomarkers more efficiently and understand the complicated pathologies of pre-eclampsia.","PeriodicalId":36268,"journal":{"name":"Journal of Clinical Obstetrics and Gynecology","volume":null,"pages":null},"PeriodicalIF":0.1000,"publicationDate":"2023-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Obstetrics and Gynecology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29328/journal.cjog.1001135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Pre-eclampsia is a pregnancy-associated condition, which is characterized by the onset of hypertension and proteinuria. It is one of the leading causes of maternal and neonatal mortality and this affliction has been recorded in around 8% of all pregnancies in the world. In addition to this, the etiopathology of this condition is very less understood and the resources available to diagnose and treat it are limited. Prior studies suggest more than a hundred possible diagnostic biomarkers that could be used to detect this disease early on. However, most of them are not feasible due to several reasons including stability, cost, safety, etc. Here two biomarkers HtrA3 (high-temperature requirement A3) and NGAL (Neutrophil Gelatinase Associated Lipocalin) are selected for the detection of pre-eclampsia, and we compare their efficacy in the detection of pre-eclampsia based on their specificity, ease of use, speed, stage of detection and source (invasiveness). We found that these two biomarkers are efficient under some parameters, and inefficient under others. The scoring system used in the current study suggests that NGAL is a superior biomarker. The results of this study help to develop a stronger understanding of both these biomarkers in the short and long term to classify the biomarkers more efficiently and understand the complicated pathologies of pre-eclampsia.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
HtrA3和NGAL作为子痫前期生物标志物的比较分析
子痫前期是一种妊娠相关的疾病,其特点是高血压和蛋白尿的发作。它是孕产妇和新生儿死亡的主要原因之一,据记录,全世界约有8%的孕妇患有此病。除此之外,这种疾病的病因尚不清楚,可用的诊断和治疗资源也很有限。先前的研究表明,有100多种可能的诊断性生物标志物可用于早期检测这种疾病。然而,由于稳定性、成本、安全性等原因,大多数都是不可行的。本文选择HtrA3(高温要求A3)和NGAL(中性粒细胞明胶酶相关脂钙蛋白)两种生物标志物用于子痫前期的检测,并根据其特异性、易用性、速度、检测阶段和来源(侵袭性)来比较它们在子痫前期的检测效果。我们发现这两种生物标志物在某些参数下是有效的,而在其他参数下是无效的。目前研究中使用的评分系统表明NGAL是一种优越的生物标志物。本研究结果有助于在短期和长期内对这些生物标志物有更深入的了解,从而更有效地对生物标志物进行分类,并了解子痫前期的复杂病理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Clinical Obstetrics and Gynecology
Journal of Clinical Obstetrics and Gynecology Medicine-Obstetrics and Gynecology
CiteScore
0.30
自引率
0.00%
发文量
8
期刊最新文献
Management of Congenital Cervical Teratoma with Application of EXIT Protocol - Case Report Reverse Breech Extraction versus Vaginal Push before Uterine Incision during Cesarean Section with Fully Dilated Cervix and Impacted Fetal Head Postdate Pregnancy Maternal and Fetal Outcomes among Sudanese Women Age as a Predictor of Time to Response for Patients Undergoing Medical Management of Endometrial Cancer Ectopic Pregnancy Risk Factors Presentation and Management Outcomes
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1